1291094-73-9

Usage

Uses

Used in Pharmaceutical Industry:
(2S,3R,4R,5S,6R)-2-(3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-4-ethylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol is used as a potential pharmaceutical candidate for various applications due to its structural complexity and the presence of functional groups.
Used in Chemical Research:
(2S,3R,4R,5S,6R)-2-(3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-4-ethylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol is used as a subject of chemical research to understand its properties and potential applications. Further research and analysis would be needed to fully understand its properties and potential applications.

Upstream product

• 1291094-65-9 6-[(2-bromo-5-iodophenyl)methyl]-2,3-dihydro-1,4-benzodioxin 
• 1291094-66-0 (3R,4S,5S,6R)-2-(4-bromo-3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)meth yl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol 
• 1291094-64-8 (2-bromo-5-iodophenyl)-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methanone 
• 1261570-98-2 2-bromo-5-iodobenzoyl chloride 
• 25252-00-0 2-bromo-5-iodobenzoic acid 

Downstream Products

• 1291095-45-8 (2S,3R,4R,5S,6R)-2-[3-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-4-ethyl-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol L-proline complex 1:1 
• 1402225-54-0 phosphoric acid (2R,3S,4R,5R,6S)-6-[3-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-4-ethyl-phenyl]-3,4,5-trihydroxy-tetrahydro-pyran-2-ylmethyl ester diethyl ester 
• 1402225-41-5 (2S,3R,4R,5S,6R)-2-[3-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-4-ethyl-phenyl]-6-trityloxymethyl-tetrahydro-pyran-3,4,5-triol 
• 1402225-44-8 (R)-2-tert-butoxycarbonylamino-3-methyl-butyric acid (2R,3R,4R,5S,6S)-3,4,5-tris-benzyloxy-6-[3-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-4-ethyl-phenyl]-tetrahydropyran-2-ylmethyl ester 
• 1402225-42-6 6-[2-ethyl-5-((2S,3S,4R,5R,6R)-3,4,5-tris-benzyloxy-6-trityloxymethyl-tetrahydropyran-2-yl)-benzyl]-2,3-dihydro-benzo[1,4]dioxine 
• 1402225-45-9 (R)-2-tert-butoxycarbonylamino-3-methyl-butyric acid (2R,3S,4R,5R,6S)-6-[3-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-4-ethyl-phenyl]-3,4,5-trihydroxy-tetrahydropyran-2-ylmethyl ester 
• 1402225-43-7 {(2R,3R,4R,5S,6S)-3,4,5-tris-benzyloxy-6-[3-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-4-ethyl-phenyl]-tetrahydro-pyran-2-yl}-methanol 
• 1402225-57-3 phosphoric acid mono-{(2R,3S,4R,5R,6S)-6-[3-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-4-ethyl-phenyl]-3,4,5-trihydroxy-tetrahydropyran-2-ylmethyl}ester 
• 1402225-46-0 (R)-2-amino-3-methyl-butyric acid (2R,3S,4R,5R,6S)-6-[3-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-4-ethyl-phenyl]-3,4,5-trihydroxy-tetrahydropyran-2-ylmethyl ester 

Relevant academic research and scientific papers

GLYCOSIDE DERIVATIVES AND USES THEREOF

The present invention provides a compound of formula I; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical compo

Glycoside Derivatives and Uses Thereof

This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.